Nuvo Pharmaceuticals Inc (TSE:NRI) hit a new 52-week low during mid-day trading on Friday . The company traded as low as C$0.46 and last traded at C$0.49, with a volume of 2560 shares. The stock had previously closed at C$0.50.
Separately, Bloom Burton downgraded shares of Nuvo Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, May 16th.
The stock’s fifty day moving average is C$0.66 and its 200-day moving average is C$1.52. The stock has a market capitalization of $6.26 million and a PE ratio of -0.24. The company has a debt-to-equity ratio of 620.32, a current ratio of 2.12 and a quick ratio of 1.43.
Nuvo Pharmaceuticals Inc, a commercial healthcare company, produces and sells pharmaceutical products in the United States, Canada, and Europe. It offers Pennsaid, a topical pain product that is used to treat the signs and symptoms of osteoarthritis of the knee; Pennsaid 2%, a follow-on product to Pennsaid for the treatment of the pain of osteoarthritis of the knee; Heated Lidocaine/Tetracaine (HLT) Patch, a topical patch that provides local analgesia prior to painful needle procedures, such as dialysis, blood draws, and pediatric needles; and Resultz, an over-the-counter product intended to kill head lice and remove their eggs from hair.
Read More: Capital gains and your 401(k) or IRA
Receive News & Ratings for Nuvo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.